JPWO2021060453A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021060453A5 JPWO2021060453A5 JP2021549032A JP2021549032A JPWO2021060453A5 JP WO2021060453 A5 JPWO2021060453 A5 JP WO2021060453A5 JP 2021549032 A JP2021549032 A JP 2021549032A JP 2021549032 A JP2021549032 A JP 2021549032A JP WO2021060453 A5 JPWO2021060453 A5 JP WO2021060453A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- azabicyclo
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 53
- 150000003839 salts Chemical class 0.000 claims 50
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 229910052731 fluorine Inorganic materials 0.000 claims 32
- 125000001153 fluoro group Chemical group F* 0.000 claims 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 31
- 206010000830 Acute leukaemia Diseases 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 230000000259 anti-tumor effect Effects 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 229910052801 chlorine Inorganic materials 0.000 claims 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 102100025372 Nuclear pore complex protein Nup98-Nup96 Human genes 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 229940043355 kinase inhibitor Drugs 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 108010054452 nuclear pore complex protein 98 Proteins 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- OJZYBHREGWMPBS-BKQYKDOASA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O OJZYBHREGWMPBS-BKQYKDOASA-N 0.000 claims 2
- XCNLTDQRDJHZSS-CUBCMZKLSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2N[C@@H]3[C@@H](CC4CC4)C[C@H]2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2N[C@@H]3[C@@H](CC4CC4)C[C@H]2CC3)=O)=C1)=O XCNLTDQRDJHZSS-CUBCMZKLSA-N 0.000 claims 2
- HDYGOYPGTRLZDI-UYNKHYJESA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)=CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)=CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O HDYGOYPGTRLZDI-UYNKHYJESA-N 0.000 claims 2
- DYQYZHIXBOKRCO-LQMDSRKXSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]([C@@H]2C3)N[C@@H]3CC2=C)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]([C@@H]2C3)N[C@@H]3CC2=C)=O)=C1)=O DYQYZHIXBOKRCO-LQMDSRKXSA-N 0.000 claims 2
- SMBODYSXRSNZIB-NMCMNSHPSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O SMBODYSXRSNZIB-NMCMNSHPSA-N 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 230000004481 post-translational protein modification Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 1
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- ZLLRSFWOWRMGRM-PZUXRTOTSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)=CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)=CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O ZLLRSFWOWRMGRM-PZUXRTOTSA-N 0.000 claims 1
- GVGCQDBICLJBBC-PZUXRTOTSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O GVGCQDBICLJBBC-PZUXRTOTSA-N 0.000 claims 1
- KYCYYALNEJSWGJ-KIFXBKRZSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O KYCYYALNEJSWGJ-KIFXBKRZSA-N 0.000 claims 1
- YPSSMDSKKQBJEP-FBNLFSDBSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O YPSSMDSKKQBJEP-FBNLFSDBSA-N 0.000 claims 1
- OWIJJQUAWRBUNY-RAXKPYPPSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)=CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)=CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O OWIJJQUAWRBUNY-RAXKPYPPSA-N 0.000 claims 1
- ADGOXJDNWNWDLJ-FPQPQGOJSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O ADGOXJDNWNWDLJ-FPQPQGOJSA-N 0.000 claims 1
- IOQIANNAMRGNDD-RAXKPYPPSA-N CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C(C)C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O IOQIANNAMRGNDD-RAXKPYPPSA-N 0.000 claims 1
- IVESAMZMRHMTJK-BJFQTCHOSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)=CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)=CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O IVESAMZMRHMTJK-BJFQTCHOSA-N 0.000 claims 1
- SXLGKLSVCVTLNP-BJFQTCHOSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O SXLGKLSVCVTLNP-BJFQTCHOSA-N 0.000 claims 1
- TVRUKSFCYVIQKY-GKPRTABNSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O TVRUKSFCYVIQKY-GKPRTABNSA-N 0.000 claims 1
- POWBBAWDKUSXNH-AUUJMIBLSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O POWBBAWDKUSXNH-AUUJMIBLSA-N 0.000 claims 1
- VAJFAKMTQLKVQW-FBOAJTAASA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CC2CC3)CC3N2C([C@H]2NC3CCC2CC3)=O)=C1)=O VAJFAKMTQLKVQW-FBOAJTAASA-N 0.000 claims 1
- DWMULEJZNQBBIS-BKQYKDOASA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]([C@@H]2CC3)N[C@@H]3CC2=C)=O)=C1)=O DWMULEJZNQBBIS-BKQYKDOASA-N 0.000 claims 1
- LRQXNPWHOZTHJX-PZUXRTOTSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O LRQXNPWHOZTHJX-PZUXRTOTSA-N 0.000 claims 1
- JPESGFKZWRAYMT-RMRMETPCSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]([C@@H]2CC3)N[C@@H]3C[C@@H]2F)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]([C@@H]2CC3)N[C@@H]3C[C@@H]2F)=O)=C1)=O JPESGFKZWRAYMT-RMRMETPCSA-N 0.000 claims 1
- YFJWHDMPNFUFGY-KIFXBKRZSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O YFJWHDMPNFUFGY-KIFXBKRZSA-N 0.000 claims 1
- REDZZBFRHWRVIZ-QYFGFFLSSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]2N[C@H]3C[C@@H]2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CCN2C([C@H]2N[C@H]3C[C@@H]2CC3)=O)=C1)=O REDZZBFRHWRVIZ-QYFGFFLSSA-N 0.000 claims 1
- IZGKMBASQYCHFK-IKLQUFJGSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O IZGKMBASQYCHFK-IKLQUFJGSA-N 0.000 claims 1
- KMMHUSWIKDLBKS-QJGDNWRMSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)C[C@H]2NC([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C(CCC2)C[C@H]2NC([C@H]2NC3CCC2CC3)=O)=C1)=O KMMHUSWIKDLBKS-QJGDNWRMSA-N 0.000 claims 1
- NTDPWBANUOVJDR-VRMDPKKPSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C2CC(C3)(CN3C([C@H]3N[C@H]4C[C@@H]3CC4)=O)CC2)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(C2CC(C3)(CN3C([C@H]3N[C@H]4C[C@@H]3CC4)=O)CC2)=C1)=O NTDPWBANUOVJDR-VRMDPKKPSA-N 0.000 claims 1
- BWVMOHBKRHGNHZ-VKDLEMAVSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(C2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(C2)CN2C([C@H]2NC3CCC2CC3)=O)=C1)=O BWVMOHBKRHGNHZ-VKDLEMAVSA-N 0.000 claims 1
- RRFVSUMDQHFATH-BYQFEBCPSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CC(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O RRFVSUMDQHFATH-BYQFEBCPSA-N 0.000 claims 1
- ZPZCSHKBNTWCLZ-QGWLYYQKSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CN(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CN(CC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O ZPZCSHKBNTWCLZ-QGWLYYQKSA-N 0.000 claims 1
- GOZFIJNFOOGESN-BYQFEBCPSA-N CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CN(CCC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O Chemical compound CC(C)N(C)C(C(C=C(C=C1)F)=C1N1C2=CN=CC=C2C(CN(CCC2)CCN2C([C@H]2NC3CCC2CC3)=O)=C1)=O GOZFIJNFOOGESN-BYQFEBCPSA-N 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000002918 testicular germ cell tumor Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019176324 | 2019-09-27 | ||
| JP2019176324 | 2019-09-27 | ||
| PCT/JP2020/036219 WO2021060453A1 (ja) | 2019-09-27 | 2020-09-25 | 架橋型光学活性２級アミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021060453A1 JPWO2021060453A1 (https=) | 2021-04-01 |
| JPWO2021060453A5 true JPWO2021060453A5 (https=) | 2023-10-02 |
| JP7618567B2 JP7618567B2 (ja) | 2025-01-21 |
Family
ID=75166233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549032A Active JP7618567B2 (ja) | 2019-09-27 | 2020-09-25 | 架橋型光学活性２級アミン誘導体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US12559487B2 (https=) |
| JP (1) | JP7618567B2 (https=) |
| WO (1) | WO2021060453A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| US20250197392A1 (en) * | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| WO2025023321A1 (en) * | 2023-07-27 | 2025-01-30 | Sumitomo Pharma Co., Ltd. | Process for preparing optically-active azabicyclo ring derivative, and intermediate for its production |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
| WO2026062248A1 (en) * | 2024-09-20 | 2026-03-26 | Acerta Pharma B.V. | Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| ES2991898T3 (es) | 2018-08-08 | 2024-12-05 | Sumitomo Pharma Co Ltd | Derivado de piperidina con puente ópticamente activo |
| KR102779601B1 (ko) | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
-
2020
- 2020-09-25 JP JP2021549032A patent/JP7618567B2/ja active Active
- 2020-09-25 WO PCT/JP2020/036219 patent/WO2021060453A1/ja not_active Ceased
- 2020-09-25 US US17/763,265 patent/US12559487B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021060453A5 (https=) | ||
| JP2024521979A5 (https=) | ||
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| JP2022062168A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| JP2022501430A (ja) | Ｓｒｃホモロジー−２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 | |
| JP2022020003A5 (https=) | ||
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| JP7208659B2 (ja) | インドリノン化合物の使用 | |
| US10786492B2 (en) | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | |
| JPWO2019189732A5 (https=) | ||
| TWI755788B (zh) | 類鐸受體促效劑 | |
| JPWO2020032105A5 (https=) | ||
| JP2015007110A (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| KR20150081344A (ko) | 조합 요법 | |
| JP2018525358A (ja) | アピリモドを用いる癌の処置方法 | |
| JP2015500884A (ja) | 癌を治療するための低酸素活性化プロドラッグおよびｍＴＯＲ阻害剤 | |
| TW202529759A (zh) | 治療癌症之方法 | |
| JP2022515670A5 (https=) | ||
| CN116261455A (zh) | 一种药物组合物及其在治疗癌症中的用途 | |
| JP2014512362A5 (https=) | ||
| RU2016135413A (ru) | Фармацевтические комбинации, включающие ингибитор pi3k, для лечения рака | |
| CA3178655A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies | |
| EP3397632B1 (en) | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |